Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,223,238 papers from all fields of science
Search
Sign In
Create Free Account
DJ927
Known as:
DJ 927
, DJ-927
A semi-synthetic orally-available taxane derivative with potent antineoplastic properties. DJ-927 binds to tubulin, promoting microtubule assembly…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
tesetaxel
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer
P. Baas
,
A. Szczesna
,
+6 authors
S. Burgers
Journal of Thoracic Oncology
2008
Corpus ID: 46312757
Introduction: A phase I/II study was performed to assess the efficacy and toxicity of a new oral taxane in patients with…
Expand
Review
2006
Review
2006
Update on tubulin-binding agents.
G. Attard
,
A. Greystoke
,
S. Kaye
,
J. D. de Bono
Pathologie et biologie
2006
Corpus ID: 43376665
2006
2006
Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer.
M. Moore
,
C. Jones
,
+7 authors
K. Felt
Journal of Clinical Oncology
2006
Corpus ID: 11465046
3591 Background: DJ-927, a novel oral tubulin depolymerization inhibitor, causes apoptosis and DNA cell division arrest. It is…
Expand
2006
2006
A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen.
T. Evans
,
R. Dobrila
,
+4 authors
D. A. Anthoney
Journal of Clinical Oncology
2006
Corpus ID: 34717974
4081 Background: Most 1st-line combination chemotherapy regimens in pts with advanced GC include 5-FU. Taxanes are also active…
Expand
2006
2006
A phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of…
A. Szczesna
,
E. Milanowski
,
+5 authors
P. Baas
Journal of Clinical Oncology
2006
Corpus ID: 33543552
17006 Background: For the treatment of NSCLC (1st and 2nd line) effective oral formulations of drugs are currently investigated…
Expand
2006
2006
641 POSTER Effecacy and prediction of response to the new oral taxane DJ-927 in anthacycline pre-treated advanced breast cancer (ABC)
S. Chan
,
R. Paridaens
,
+7 authors
A. Jenner
2006
Corpus ID: 71598495
2005
2005
Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses
J. Rhee
,
F. Lee
,
+8 authors
P. Hoff
2005
Corpus ID: 74363278
2004
2004
Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers.
S. Syed
,
M. Beeram
,
+7 authors
P. LoRusso
Journal of Clinical Oncology
2004
Corpus ID: 27752584
2028 Background: DJ-927, a novel semi-synthetic taxane and a poor substrate of P-glycoprotein (Pgp), is orally bioavailable and…
Expand
2004
2004
Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys.
Chiho Ono
,
A. Takao
,
R. Atsumi
Biological and Pharmaceutical Bulletin
2004
Corpus ID: 2285557
DJ-927, currently undergoing Phase I clinical trial, is a new orally effective taxane with potent antitumor effects. The…
Expand
Highly Cited
2003
Highly Cited
2003
DJ‐927, a novel oral taxane, overcomes P‐glycoprotein‐mediated multidrug resistance in vitro and in vivo
M. Shionoya
,
T. Jimbo
,
Mayumi Kitagawa
,
T. Soga
,
A. Tohgo
Cancer Science
2003
Corpus ID: 32605561
DJ‐927 is a novel taxane, which was selected for high solubility, non‐neurotoxicity, oral bioavailability, and potent antitumor…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE